革命药品错过了收入估算, 看到内幕出售, 并且有一个负P/E, 尽管“Buy”共识。 Revolution Medicines missed earnings estimates, saw insider selling, and has a negative P/E, despite a "Buy" consensus.

革命药品公司(RVMD)报告每季度每股损失1.86美元,估计损失0.30美元,因为临床阶段生物制药公司将重点放在依赖RAS的癌症上。 Revolution Medicines (RVMD) reported a quarterly loss of $1.86 per share, missing estimates by $0.30, as the clinical-stage biopharma company focuses on RAS-dependent cancers. HighVista战略公司股份增加了157.8%,达到175 448股,价值约819万美元,而Holcene顾问公司股份减少了195 669股。 HighVista Strategies increased its stake by 157.8% to 175,448 shares, worth about $8.19 million, while Holocene Advisors reduced its position by 195,669 shares. 股票开放额为94.86美元,市场上限为188亿美元,P/E比率为负16.05。 The stock opened at $94.86 with a market cap of $18.8 billion and a negative P/E ratio of -16.05. 分析员维持协商一致的“Buy”评级,目标价为78.94美元。 Analysts maintain a consensus “Buy” rating with a target price of $78.94. 该公司的输油管包括RMC-4630、RMC-6291和RMC-6236,目标是不可药的RAS/MAPK路径蛋白质。 The company’s pipeline includes RMC-4630, RMC-6291, and RMC-6236, targeting undruggable RAS/MAPK pathway proteins. 机构投资者拥有94.34%的股票,最近的内幕销售总额达149 792股,90天内价值1 438万美元。 Institutional investors own 94.34% of shares, and recent insider sales totaled 149,792 shares valued at $14.38 million over 90 days.